|Articles|June 1, 2002
Latanoprost plus brimonidine controls IOP
Austin, TX-Patients who need more than one ocular hypotensive agent to achieve low IOP may benefit more from a regimen of latanoprost (Xalatan, Pharmacia) and adjunctive brimonidine (Alphagan, Allergan) than from dual therapy with latanoprost and timolol, according to a recent study.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
NCX 470 gains positive regulatory feedback in China ahead of US NDA submission
2
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
3
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)
4
Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy
5

















